Savolitinib is a highly selective mesenchymal-epithelial transition factor (MET) tyrosine kinase inhibitor (TKI) used primarily for treating NSCLC with MET exon 14 skipping mutations (5). This evidence concerns the gene MET and non-small cell lung carcinoma.